Financial Performance - Total Net Sales for Q3 2025 were $1.495 billion, flat compared to Q3 2024, with a 3% decrease in volume and a 1% increase in price [4]. - Net Income attributable to Chemours was $60 million, or $0.40 per diluted share, compared to a Net Loss of $32 million, or $(0.22) per diluted share in Q3 2024, representing a 288% year-over-year improvement [8]. - Adjusted EBITDA for Q3 2025 was $195 million, a decrease of 3% from $202 million in Q3 2024, primarily due to increased costs from operational disruptions [9]. - Free Cash Flow for Q3 2025 was $105 million, reflecting a Free Cash Flow Conversion of 54% [24]. - The company anticipates a sequential Net Sales decrease of 10-15% in Q4 2025, with Adjusted EBITDA expected to range between $130 million and $160 million [25]. - Gross profit for Q3 2025 was $233 million, down 18.5% from $286 million in Q3 2024 [37]. - Adjusted net income for the three months ended September 30, 2025, was $30 million, down from $61 million in the same period of 2024 [48]. - For the three months ended September 30, 2025, Chemours reported a net income of $60 million, compared to a net loss of $32 million in the same period of 2024 [51]. - Adjusted Net Income for the nine months ended September 30, 2025, was $165 million, down from $137 million in the same period of 2024 [51]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $614 million, compared to $600 million in the same period of 2024 [54]. - The estimated Adjusted EBITDA for the year ending December 31, 2025, is projected to be between $745 million and $770 million [55]. - Chemours expects a net loss attributable to the company in the range of $318 million to $335 million for the year ending December 31, 2025 [55]. Segment Performance - The Thermal & Specialized Solutions segment reported Net Sales of $560 million, a 20% increase year-over-year, driven by an 80% increase in Opteon™ Refrigerants [10]. - Titanium Technologies segment Net Sales decreased by 9% to $612 million, primarily due to an 8% decrease in price globally [13]. - Advanced Performance Materials segment Net Sales were $311 million, a 12% decrease year-over-year, driven by a 15% decrease in volume [17]. - The Titanium Technologies segment reported net sales of $612 million for the three months ended September 30, 2025, a decrease of 9% compared to the same period in 2024 [45]. - The Advanced Performance Materials segment experienced a 12% decline in net sales, totaling $311 million for the three months ended September 30, 2025 [45]. Cash Flow and Assets - Cash provided by operating activities for the nine months ended September 30, 2025, was $127 million, a significant recovery from cash used of $771 million in the same period of 2024 [41]. - Total current assets increased to $3,207 million as of September 30, 2025, up from $3,017 million at the end of 2024 [39]. - Total liabilities rose to $7,270 million as of September 30, 2025, compared to $6,925 million at the end of 2024 [39]. - Free Cash Flows for the three months ended September 30, 2025, were $105 million, an increase from $63 million in the same period of 2024 [54]. - The Free Cash Flow Conversion rate for the three months ended September 30, 2025, was 54%, compared to 31% in the previous quarter [54]. Corporate Strategy and Agreements - A strategic agreement was announced with SRF Limited in India to support market needs for essential applications [8]. - The company anticipates guidance for Q2 2025 and full year 2025 performance, reflecting a refreshed corporate strategy [34]. Impairments and Charges - The company reported a goodwill impairment charge of $56 million in Q3 2024, which was not repeated in Q3 2025 [37]. - Litigation-related charges for the twelve months ended September 30, 2025, included $263 million related to a settlement agreement with the State of New Jersey [1]. - Environmental charges for the twelve months ended September 30, 2025, primarily included changes to remediation reserves at sites covered by the New Jersey settlement agreement [1]. Debt and Leverage - The net leverage ratio calculated using non-GAAP earnings was 4.6x for the three months ended September 30, 2025 [48]. - The total debt principal, net of cash and cash equivalents, was $3,572 million as of September 30, 2025 [48]. - The net leverage ratio calculated using GAAP measures is defined as total debt principal, net, divided by income before income taxes [1].

Core Viewpoint - Chemours has announced a fourth quarter dividend, indicating a commitment to returning value to shareholders and reflecting the company's financial health [1] Company Summary - The dividend announcement is part of Chemours' ongoing strategy to enhance shareholder returns [1] - The specific amount of the dividend has not been disclosed in the provided content [1] Industry Summary - The announcement of dividends is a common practice in the chemical industry, often signaling strong performance and stability within the sector [1]

Core Insights - The article focuses on Chemours Company (NYSE: CC) and provides insights ahead of its quarterly reports [1] Group 1 - The author has a long position in Chemours shares, indicating a positive outlook on the company's performance [1] - The article continues a tradition of reporting on Chemours before its quarterly earnings announcements, suggesting a consistent interest in the company's financial health [1]

Core Points - Chemours has announced the dates for its third quarter 2025 earnings release and webcast conference call [1] Company Information - The earnings release and conference call are part of Chemours' regular financial reporting schedule [1]

Core Insights - The U.S. industrial sector is facing challenges due to changing consumer and business spending, inflation expectations, and new trade tariffs, but opportunities exist for investors with the right positioning [2] Group 1: Chemours Co. (CC) - Chemours is not typically viewed as a consumer play, but its chemicals are essential in automotive and housing paints, which could benefit from recent Federal Reserve interest rate cuts [3][4] - The stock is currently priced at $16.11 with a 52-week range of $9.13 to $22.38 and a dividend yield of 2.17% [3] - Analysts have set a price target of $21 per share, indicating a potential upside of 36% from the current price [5] Group 2: Dow Inc. (DOW) - Dow's stock is currently at $23.84, with a 52-week range of $20.40 to $55.63 and a dividend yield of 5.87% [8] - Lower interest rates are expected to stimulate new business activity, leading to increased demand for restocking inventories, particularly in packaging materials [8][9] - The current consensus price target for Dow is $30 per share, suggesting a potential upside of 30.2% from its current trading price [10] Group 3: Nucor Corp. (NUE) - Nucor, the largest U.S. steelmaker, is well-positioned to benefit from rebounds in both residential and industrial construction due to infrastructure spending [12] - The stock is currently priced at $137.98, with a 52-week range of $97.59 to $170.52 and a dividend yield of 1.59% [11] - Nucor reported an EPS of $2.60 for the recent quarter, exceeding the consensus estimate, and is expected to see cost reductions while prices rise due to increased demand [14]

Group 1 - The Chemours Company (NYSE:CC) is considered one of the best specialty chemicals stocks to invest in, with Mizuho maintaining an Outperform rating and raising its price target from $16 to $19 due to higher market multiples [1] - Mizuho highlighted growing concerns over shared PFAS liabilities amid the impending DuPont split and other corporate changes, but noted that Chemours is not trading as if there is a significant PFAS tail risk, suggesting limited lingering liability unless bankruptcy occurs [2] - The Chemours Company manufactures a range of industrial and specialty products across various industries, including coatings, plastics, semiconductors, transportation, oil and gas, and refrigeration and air conditioning [3]

Group 1 - The Chemours Company (NYSE:CC) is considered chronically undervalued, despite concerns regarding "forever chemicals" which are believed to be behind the company [1] - Chemours delivers specialty chemicals across various industries, including refrigerants, pigments, resins, coatings, and advanced materials for applications in electronics, packaging, energy, transportation, and medical fields [1] - Mizuho analyst John Roberts raised Chemours' price target to $19 from $16 while maintaining an Outperform rating, citing favorable settlement progress regarding per- and polyfluoroalkyl substances and stronger market valuations [1]

Group 1 - The Chemours Company (NYSE:CC) is considered one of the best undervalued stocks to invest in, according to Reddit discussions [1] - Truist raised the price target for Chemours' stock from $18 to $21 while maintaining a "Buy" rating, indicating confidence in the company's future performance [1] - The TiO2 industry is showing signs of pricing discipline and production curtailments, which are expected to contribute to earnings growth for Chemours [1] Group 2 - In Q2 2025, Chemours reported net sales of $1.6 billion, a 4% increase compared to the same quarter last year, driven by a 3% rise in volume and a 1% rise in price [2] - The company's results exceeded expectations, with improvements across all three business segments, supported by strong demand for Opteon™, volume growth in TT, and favorable pricing in APM [2]

Group 1 - Chemours Company signed strategic agreements with SRF Limited to enhance its global supply chain and operational flexibility [1][8] - The partnership allows Chemours to access SRF's manufacturing capacity for fluoropolymers and fluoroelastomers, supporting a shift towards higher value applications without upfront capital investment [2][8] - SRF's expertise in complex chemical production is expected to strengthen its position as a trusted manufacturer of advanced materials through this collaboration [3] Group 2 - For Q3 2025, Chemours anticipates a sequential decrease in consolidated net sales by 4-6% and adjusted EBITDA in the range of $175-$195 million [6] - Full-year 2025 sales are projected between $5.9 billion and $6 billion, with adjusted EBITDA expected to be between $775 million and $825 million [7] - Capital expenditures for 2025 are forecasted to be approximately $250 million [7] Group 3 - Chemours' stock has declined by 16% over the past year, compared to a 20.6% decline in the industry [5] - The company currently holds a Zacks Rank of 4 (Sell), while other stocks in the Basic Materials sector, such as CF Industries and Nutrien, have better rankings [8]

Core Insights - The Chemours Company reported a net loss of $381 million or $2.54 per share for Q2 2025, compared to a net income of $60 million or 39 cents in the same quarter last year [1] - Adjusted earnings were 58 cents per share, exceeding the Zacks Consensus Estimate of 46 cents [1] Financial Performance - Q2 2025 net sales reached $1,615 million, a 4% increase from the previous year, surpassing the Zacks Consensus Estimate of $1,568.3 million [2] - Adjusted EBITDA improved by 22% year-over-year to $253 million, driven by volume growth, pricing, and lower corporate expenses [2] - Cash used by operating activities in the first half of 2025 was $19 million, significantly lower than $910 million in the prior-year period [6] Segment Performance - Titanium Technologies division revenues were $657 million, a 3% decrease year-over-year, but above the estimate of $640.1 million, primarily due to a 4% decrease in price [3] - Thermal & Specialized Solutions segment revenues increased by 15% year-over-year to $597 million, driven by an 11% increase in volume and a 4% increase in price, exceeding the estimate of $582.6 million [4] - Advanced Performance Materials unit revenues were flat at $346 million year-over-year, beating the estimate of $332.9 million, with a 6% decrease in volume offset by a 6% increase in pricing [5] Future Outlook - For Q3 2025, the company expects consolidated net sales to decrease by 4-6% sequentially, with adjusted EBITDA projected between $175 million and $195 million [7] - Full-year 2025 sales are expected to be between $5.9 billion and $6 billion, with adjusted EBITDA between $775 million and $825 million [8] Stock Performance - Chemours shares have declined by 32.1% over the past year, compared to a 23.1% decline in the industry [9]